164 related articles for article (PubMed ID: 10787220)
1. Should women at increased risk for breast and ovarian cancer be randomized to prophylactic surgery? An ethical and empirical assessment.
Tambor ES; Bernhardt BA; Geller G; Helzlsouer KJ; Doksum T; Holtzman NA
J Womens Health Gend Based Med; 2000 Apr; 9(3):223-33. PubMed ID: 10787220
[TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
3. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.
Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K
Gynecol Oncol; 1999 Oct; 75(1):122-9. PubMed ID: 10502438
[TBL] [Abstract][Full Text] [Related]
4. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines.
Julian-Reynier C; Eisinger F; Moatti JP; Sobol H
Eur J Hum Genet; 2000 Mar; 8(3):204-8. PubMed ID: 10780786
[TBL] [Abstract][Full Text] [Related]
5. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
6. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer.
Eisen A; Rebbeck TR; Wood WC; Weber BL
J Clin Oncol; 2000 May; 18(9):1980-95. PubMed ID: 10784640
[TBL] [Abstract][Full Text] [Related]
8. Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer.
Antill Y; Reynolds J; Young MA; Kirk J; Tucker K; Bogtstra T; Wong S; Dudding T; Di Iulio J; Phillips KA
Eur J Cancer; 2006 Mar; 42(5):621-8. PubMed ID: 16434187
[TBL] [Abstract][Full Text] [Related]
9. A survey of preventive measures among BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
[TBL] [Abstract][Full Text] [Related]
10. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
11. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
12. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
[TBL] [Abstract][Full Text] [Related]
13. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
14. Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast cancer.
Nayfield SG
J Cell Biochem Suppl; 1996; 25():123-30. PubMed ID: 9027608
[TBL] [Abstract][Full Text] [Related]
15. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
16. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
18. Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys.
Eisinger F; Stoppa-Lyonnet D; Lasset C; Vennin P; Chabal F; Noguès C; Moatti JP; Sobol H; Julian-Reynier C
Fam Cancer; 2001; 1(3-4):157-62. PubMed ID: 14574172
[TBL] [Abstract][Full Text] [Related]
19. The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.
Borreani C; Manoukian S; Bianchi E; Brunelli C; Peissel B; Caruso A; Morasso G; Pierotti MA
Clin Genet; 2014 Jan; 85(1):7-15. PubMed ID: 24117034
[TBL] [Abstract][Full Text] [Related]
20. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
